Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta Academic Article uri icon

Overview

MeSH Major

  • Alendronate
  • Bone Density Conservation Agents
  • Osteogenesis Imperfecta
  • Osteoporotic Fractures
  • Recombinant Fusion Proteins

abstract

  • Treatment of oim/oim mice with either a bisphosphonate or a RANK-Fc causes similar decreases in fracture incidence with increases in metaphyseal bone volume via increased number of thinner trabeculae.

publication date

  • March 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3922057

Digital Object Identifier (DOI)

  • 10.1007/s00198-011-1742-7

PubMed ID

  • 21901481

Additional Document Info

start page

  • 1141

end page

  • 50

volume

  • 23

number

  • 3